Azacitidine
Myelodysplastic Syndrome With Excess Blasts
Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Apollo Therapeutics Ltd
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06372717CT.gov A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS | — | Recruiting | — | — | — |
NCT03383575CT.gov Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome | — | Recruiting | — | — | — |
NCT03047993CT.gov Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT01522976CT.gov Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia | — | Active Not Recruiting | — | — | — |
NCT01168219CT.gov Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00392353CT.gov Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myelodysplastic Syndrome With Excess Blasts
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Azacitidine (this asset) | Apollo Therapeutics Ltd | P2 | BB · 69 |
| Cytarabine | University of Southern California | P3 | BBB |
| Tacrolimus | Fred Hutchinson Cancer Center | P2 | BB |
| Fludarabine | Fred Hutchinson Cancer Center | P3 | BB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | BB |
| Idarubicin | Fred Hutchinson Cancer Center | P3 | BB |
| Etoposide | M.D. Anderson Cancer Center | P3 | BB |
| Cyclophosphamide | Fred Hutchinson Cancer Center | P3 | BB |
| Dexasone | National Cancer Institute (NCI) | P3 | BB |
+42 more in the Myelodysplastic Syndrome With Excess Blasts cohort
Other indications for Azacitidine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 73 |
| Acute Erythroid Leukemia | — | P2 | BB · 71 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Azacitidine in Myelodysplastic Syndrome With Excess Blasts. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/azacitidine-myelodysplastic-syndrome-with-excess-blasts
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →